Core Viewpoint - The company, Jianfan Bio, has announced that its controlling shareholder and actual controller, Mr. Dong Fan, will transfer 1,264,320 units of "Jianfan Convertible Bonds" by September 22, 2025, which represents 12.64% of the total issued convertible bonds [1] Group 1 - The transfer of convertible bonds is part of a planned divestment by the controlling shareholder [1] - The total amount of convertible bonds being transferred is significant, indicating a strategic move by the shareholder [1] - The transaction will take place through the Shenzhen Stock Exchange trading system [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-073 债券代码：123117 债券简称：健帆转债 二、债券持有人历次可转债持有比例变动情况 截至 2025 年 9 月 16 日，公司控股股东、实际控制人董凡先生通过深圳证券 交易所交易系统转让其所持有的"健帆转债"1,319,814 张，占本次发行可转换 公司债券总量的 13.20%。转让后董凡先生持有"健帆转债"3,037,830 张，占本 次发行可转换公司债券总量的 30.38%。具体内容详见公司 2025 年 9 月 17 日刊 载于巨潮资讯网（www.cninfo.com.cn）的《关于债券持有人可转债持有比例变 动达到 10%的公告》（公告编号：2025-072）。 公司于近日收到控股股东、实际控制人董凡先生的通知，截至 2025 年 9 月 22 日，董凡先生通过深圳证券交易所交易系统转让其所持有的"健帆转债" 1,264,320 张，占本次发行可转换公司债券总量的 12.64%，具体变动情况如下： 1 健帆生物科技集团股份有限公司 关于债券持有人可转债持有比例变动达到 10%的公告 本公司及董事会全体成员保证信息披露的内容真实、 ...

Core Viewpoint - The article emphasizes the importance of improving the quality of life for patients with uremia through innovative treatment options and social responsibility initiatives, particularly highlighting the role of Jianfan Group in this endeavor [3][14]. Group 1: Medical Innovations - Over 3 million patients globally rely on dialysis, facing challenges in self-management and treatment delays, which affect their life expectancy [1] - Jianfan Group developed the HA130 blood perfusion device in 2004, which effectively removes medium and large molecular toxins that traditional dialysis cannot, filling a significant gap in treatment options [5][6] - The company has published over 3,000 clinical papers, with more than 300 included in international journals, establishing a strong evidence base for its products [6] Group 2: Clinical Application and Standardization - Jianfan has conducted extensive clinical trials, leading to the inclusion of its blood perfusion technology in clinical standard operating procedures and expert consensus guidelines [6][7] - The combination of dialysis and perfusion has been recognized as a standard treatment option, supported by a robust training and operational guideline framework [7] Group 3: Policy and Economic Impact - Recent healthcare reforms in China have made blood purification treatments more accessible and affordable for patients, with new guidelines for dialysis perfusion services introduced by the National Healthcare Security Administration [8] - Jianfan has responded to these reforms by reducing the prices of its perfusion devices while maintaining quality, thus enhancing patient access to innovative treatments [8] Group 4: Global Expansion and Market Position - Jianfan's blood perfusion technology has gained international recognition, with products entering over 8,000 hospitals worldwide and holding a market share of over 70% in the blood perfusion sector [10] - The company has obtained CE certification for multiple products, facilitating its entry into global markets and showcasing the success of Chinese innovation in high-end medical devices [10][11] Group 5: Social Responsibility and Community Engagement - Jianfan has established a dual system for corporate social responsibility, focusing on healthcare initiatives and community support, including the establishment of "Uremia Care Day" to raise awareness [12][14] - The company aims to unite government, medical institutions, and social organizations to protect the dignity of patients, exemplified by success stories of patients regaining mobility through their treatments [12][14]

Group 1: Stock Performance and Investor Relations - The company's stock price has recently declined due to various factors, and management is considering measures such as share buybacks and stock purchases to boost investor confidence [1][2] - The company has implemented multiple strategies, including cash dividends and stock incentive plans, to enhance investor trust [2] Group 2: Project Development and Market Potential - The polyethersulfone project is currently in the R&D phase and has not yet reached mass production; future revenue projections will be disclosed in regular reports [2] - The company has been recognized by the Ministry of Industry and Information Technology and the National Medical Products Administration for its innovative biomedical materials [2] Group 3: Sales and Marketing Strategies - The company emphasizes the need for ongoing investment in sales expenses to promote new technologies and products in the clinical setting [3] - The blood purification industry is still in its early stages, necessitating significant market promotion efforts [3] Group 4: Health Management Initiatives - The company is actively exploring new business areas related to metabolic cardiovascular diseases and health management, responding to national health initiatives [4] - A major clinical study on plasma adsorption in stroke patients has been initiated, showing promising preliminary results [4] Group 5: Product Pricing and Market Impact - The blood purification products have not yet been included in centralized procurement, but there is a possibility for future inclusion, which could affect pricing and profit margins [5] - The company is preparing for potential impacts from centralized procurement policies, focusing on quality competition rather than just price [5] Group 6: Research and Development Focus - The company invests over 200 million annually in R&D, having registered 11 new products since 2022 [11] - The R&D strategy includes developing various blood purification products targeting different diseases, maintaining a competitive edge in the industry [10] Group 7: International Expansion and Market Strategy - The company is prioritizing international market expansion, having achieved product entry in 98 countries and established a presence in over 2000 hospitals abroad [18] - The focus is on academic promotion and collaboration to enhance global awareness of blood adsorption technology [18] Group 8: Regulatory and Policy Developments - Recent policy changes have officially included blood purification and plasma adsorption in the medical insurance reimbursement list, which is expected to accelerate product promotion [19] - The company is committed to timely and accurate information disclosure to protect investor rights [19]

Core Viewpoint - The company, Jianfan Bio (300529.SZ), has announced that its controlling shareholder and actual controller, Mr. Dong Fan, will transfer 1,319,814 shares of "Jianfan Convertible Bonds" through the Shenzhen Stock Exchange by September 16, 2025, which represents 13.20% of the total issued convertible bonds [1] Group 1 - The transfer of convertible bonds is part of a planned divestment by the controlling shareholder [1] - The total amount of convertible bonds being transferred is significant, indicating a strategic move by the shareholder [1] - The transaction will take place via centralized bidding on the Shenzhen Stock Exchange [1]

Core Points - The company, Jianfan Bio, announced that its controlling shareholder and actual controller, Mr. Dong Fan, will transfer 1,319,814 shares of "Jianfan Convertible Bonds" through the Shenzhen Stock Exchange by September 16, 2025, which represents 13.20% of the total issued convertible bonds [1] Summary by Category - **Company Actions** - Mr. Dong Fan will transfer a total of 1,319,814 convertible bond shares [1] - This transfer is planned to be executed via centralized bidding on the Shenzhen Stock Exchange [1] - **Ownership Impact** - The transferred shares account for 13.20% of the total amount of convertible bonds issued by the company [1]

债券代码：123117 债券简称：健帆转债 证券代码：300529 证券简称：健帆生物 公告编号：2025-071 为进一步加强与投资者的互动交流，健帆生物科技集团股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会与深圳市全景网络有限 公司联合举办的"向新提质 价值领航——2025 年广东辖区投资者网上集体接待 日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 9 月 19 日（周五）15:30-17:00。届时公司 董事长兼总经理董凡先生、董事兼财务总监廖雪云女士、董事会秘书黄聪女士以 及独立董事徐焱军先生将在线就 2025 年半年度业绩、发展战略、经营状况等投 资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 健帆生物科技集团股份有限公司董事会 2025 年 9 月 17 日 1 健帆生物科技集团股份有限公司 关于参加 2025 年广东辖区投资者 网上集体接待日活动的公告 本 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-072 债券代码：123117 债券简称：健帆转债 关于债券持有人可转债持有比例变动达到 10%的公告 健帆生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、可转换公司债券基本概况及配售情况 经中国证券监督管理委员会"证监许可[2020]3617 号"文同意注册，健帆生 物科技集团股份有限公司（以下简称"公司"）于 2021 年 6 月 23 日向不特定对 象发行了 1,000 万张可转换公司债券，每张面值 100 元，发行总额人民币 100,000 万元。经深交所同意，公司 100,000 万元可转换公司债券于 2021 年 7 月 12 日起 在深交所挂牌交易，债券简称"健帆转债"，债券代码"123117"。 公司控股股东、实际控制人董凡先生通过配售认购"健帆转债"共计4,357,644 张，占发行总量的43.58%。具体内容详见公司2021年7月7日刊载于巨潮资讯网 （www.cninfo.com.cn）的《健帆生物科技集团股份有限公司创业板向不特定对 象发行可转 ...

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds, maintaining the current terms for the time being [2]. Summary by Relevant Sections - **Company Decision**: On September 12, 2025, the company held its 32nd meeting of the fifth board of directors, where it approved the proposal not to adjust the conversion price of the "Jianfan Convertible Bonds" downward [2]. - **Future Conditions**: The next period for recalculating the conditions for triggering a downward adjustment of the conversion price will start from the first trading day after September 12, 2025. If the conditions are triggered again, the company will follow the relevant procedures to decide whether to exercise the right to adjust the conversion price downward [2].

Group 1 - The core point of the article is that Jianfan Biological announced the results of its board meeting and discussed the proposal not to adjust the conversion price of its convertible bonds [1] - For the fiscal year 2024, Jianfan Biological's revenue composition is heavily weighted towards the medical device manufacturing sector, which accounts for 99.71% of total revenue, while other sectors contribute only 0.29% [1] - As of the report date, Jianfan Biological has a market capitalization of 19 billion yuan [1]